{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:32Z","timestamp":1787027072516,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, irrespective of diabetic status. We aimed to investigate the effects of dual SGLT1\/2 inhibition, using sotagliflozin, on cardiac outcomes in normal diet (ND) and high fat diet (HFD) mice with cardiac pressure overload. Five-week-old male C57BL\/6J mice were randomized to receive a HFD (60% of calories from fat) or remain on ND for 12 weeks. One week later, transverse aortic constriction (TAC) was employed to induce cardiac pressure-overload (50% increase in right:left carotid pressure versus sham surgery), resulting in left ventricular hypertrophic remodeling and cardiac fibrosis, albeit preserved ejection fraction. At 4 weeks post-TAC, mice were treated for 7 weeks by oral gavage once daily with sotagliflozin (10 mg\/kg body weight) or vehicle (0.1% tween 80). In ND mice, treatment with sotagliflozin attenuated cardiac hypertrophy and histological markers of cardiac fibrosis induced by TAC. These benefits were associated with profound diuresis and glucosuria, without shifts toward whole-body fatty acid utilization, increased circulating ketones, nor increased cardiac ketolysis. In HFD mice, sotagliflozin reduced the mildly elevated glucose and insulin levels but did not attenuate cardiac injury induced by TAC. HFD mice had vacuolation of proximal tubular cells, associated with less profound sotagliflozin-induced diuresis and glucosuria, which suggests dampened drug action. We demonstrate the utility of dual SGLT1\/2 inhibition in treating cardiac injury induced by pressure overload in normoglycemic mice. Its efficacy in high fat-fed mice with mild hyperglycemia and compromised renal morphology requires further study.<\/jats:p>","DOI":"10.3389\/fphys.2021.738594","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T02:16:11Z","timestamp":1632190571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Sotagliflozin, a Dual SGLT1\/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload"],"prefix":"10.3389","volume":"12","author":[{"given":"Sophia L.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Steane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Bielefeldt-Ohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Reichelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/circulationaha.115.017355","article-title":"The Failing Heart Relies on Ketone Bodies as a Fuel.","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","article-title":"SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy.","volume":"49","author":"Banerjee","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/nejmoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"B8","first-page":"F118","article-title":"Structural and functional changes in the kidneys of high-fat diet-induced obese mice.","volume":"296","author":"Deji","year":"2009","journal-title":"Am. J. Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"B12","first-page":"H838","article-title":"New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans.","volume":"320","author":"Ferte","year":"2021","journal-title":"Am. J. Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/circulationaha.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences.","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130605","article-title":"Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.","volume":"10","author":"Kashiwagi","year":"2015","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/circulationaha.117.029190","article-title":"Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/circulationaha.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/nep.13713","article-title":"Validation of non-invasive transcutaneous measurement for glomerular filtration rate in lean and obese C57BL\/6J mice.","volume":"25","author":"Mullins","year":"2020","journal-title":"Nephrology"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","article-title":"Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.","volume":"20","author":"Polidori","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B24","article-title":"A High-throughput method for measurement of glomerular filtration rate in conscious mice.","volume":"75","author":"Rieg","year":"2013","journal-title":"J. Vis. Exp."},{"key":"B25","first-page":"F188","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B28","first-page":"R858","article-title":"Modeling heart failure risk in diabetes and kidney disease: limitations and potential applications of transverse aortic constriction in high-fat-fed mice.","volume":"314","author":"Tan","year":"2018","journal-title":"Am. J. Physiol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch."},{"key":"B31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"B33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a Dual SGLT1\/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial.","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clinthera.2014.10.026","article-title":"LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.","volume":"37","author":"Zambrowicz","year":"2015","journal-title":"Clin. Ther."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.738594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T02:16:26Z","timestamp":1632190586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2021.738594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":34,"alternative-id":["10.3389\/fphys.2021.738594"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2021.738594","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"article-number":"738594"}}